drugset / Trial / NCT00139724

Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet

NCT00139724

Phase 3 Completed 260 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder

Timeline

Start
2005-05
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule

Indications

No indication recorded.